PEPTIDEREPORT

Video claim watch

What Is a GLP-1 Agonist, and How Does It Work?

A brief academic-medical explanation provides a useful contrast with longer creator-led GLP-1 narratives.

Ohio State Wexner Medical Center channel1:27 runtime127K views when checked

Published Dec 10, 2024. Metadata checked Jul 12, 2026.

Watch on YouTube

Transcript review

4 material claims logged

Editorial review complete audit stateauto-captioned transcript0 operational-guidance flags0 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

concise, institutionally sourced mechanism explainer.

auto-caption available; no chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:00:21
Mechanism

says receptors in brain/GI tract contribute to appetite, hunger, satiety, and glucose regulation.

Review topic: mechanism.

Checked against: Wegovy prescribing information

00:01:06
High-risk evidence claimHigh-risk mechanism claim

says semaglutide reduces major cardiovascular events and suggests mechanisms may be partly independent of weight loss.

Review topic: CV outcomes/mechanism.

Checked against: FDA approves Wegovy cardiovascular risk reduction indication

independence is mechanistic inference, not the approved endpoint.

Connected research

Compounds discussed

Semaglutide Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Off-label, compounded, and broader behavioral claims require separate evidence and regulatory review.

Source check

Records used in this claim audit